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Background: The number of PCI has been increasing during the last years in Europe. Little is known about the characteristics of interventional 
treatment of in-stent-re-stenosis (ISR) in clinical practice in Europe.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were enrolled into the PCI-Registry of the Euro Heart Survey 
Programme to document patient characteristics, PCI details and hospital complications in different PCI indications. We examined the differences 
between treatment of ISR versus de novo-lesions in patients undergoing PCI for ACS in clinical practice.
Results: A total of 14,011 patients underwent PCI for ACS, in 789 (5.6%) the treated culprit lesion was an ISR. Patients with ISR more often were 
male; more often had diabetes, prior MI and CABG than patients undergoing PCI in de-novo lesions. No differences were found in the use of anti-
thrombotic drugs despite a more frequent use of GP IIb/IIIa receptor blockers even in patients with de-novo lesions rather than in ISR. In ISR, 70.1% 
of patients did receive a stent, of which 64.6% were DES. The rate of stenting in de-novo lesions was 94.8%, with a relative proportion of 38.0% of 
DES. No differences were observed in hospital outcome.
Conclusions: The culprit lesion in consecutive patients undergoing PCI for ACS in clinical practice in Europe was ISR in 5.6%. Patients with ACS 
treated for ISR less often received new stents, of which only two third were DES. 
ISR
n=789
De-novo stenosis n=13,222 p-value
Age [years]
Female Gender
65
22.1 %
64
27.1 %
=0.36
<0.01
Prior MI
Prior CABG
PAD
61.2 %
10.8 %
8.4 %
21.4 %
3.9 %
5.4 %
<0.001
<0.001
<0.001
Diabetes
Insulin Tx
29.2 %
27.5 %
21.6 %
24.2 %
<0.01
=0.27
Stent Implantation
Relative DES
70.1 %
64.6 %
94.8 %
38.0 %
<0.001
<0.001
GP IIb/IIIa
Heparin
LMWH
Bivalirudin
38.9 %
83.3 %
29.5 %
1.6 %
42.5 %
81.6 %
29.7 %
1.1 %
=0.05
=0.24
=0.92
=0.19
Death
MI
Death / MI / Stroke
4.3 %
3.5 %
7.1 %
3.6 %
3.8 %
7.2 %
=0.31
=0.67
=0.95
